Skip to main content

Table 2 PTV dose parameters for four plans

From: A comparative dosimetric study of left sided breast cancer after breast-conserving surgery treated with VMAT and IMRT

 

2FIMRT

4FIMRT

2ArcVMAT

1ArcVMAT

D98 (Gy)

46.2 ± 0.6 A

46.4 ± 0.4

46.6 ± 0.4 B

46.6 ± 0.6 B

D50 (Gy)

50.7 ± 0.5 A

50.2 ± 0.3 B,a

49.7 ± 0.5 B,b

49.7 ± 0.6 B,b

D2 (Gy)

53.8 ± 0.7 A

53.5 ± 0.5 A

52.5 ± 0.6 B

52.5 ± 1.1

V107

4.6 % ± 5.4 % A

2.2 % ± 1.8 % a

0.6 % ± 1.1 % B

0.7 % ± 0.9 % B,b

HI

0.150 ± 0.022 A

0.140 ± 0.016 A

0.118 ± 0.018 B

0.120 ± 0.029 B

CI

1.34 ± 0.10 A

1.32 ± 0.10 A

1.24 ± 0.07 B,a

1.16 ± 0.05 B,b

CN

0.677 ± 0.050 A

0.685 ± 0.051 A

0.728 ± 0.036 B,a

0.781 ± 0.032 B,b

MU

265.8 ± 15.6 A,b

353.1 ± 41.0 A,a

494.1 ± 54.5 B,b

598.3 ± 93.9 B,a

Time (Second)

115.8 ± 10.0 A

206.3 ± 25.0 B,a

160.9 ± 17.6 B,b

189.1 ± 27.0 B,a

  1. “A” is statistically significantly different from “B” (p < 0.05); “a” is statistically significantly different from “b” (p < 0.05). No other statistically significant difference was found between any two (p > 0.05)